Half Year 2026 Pro Medicus Ltd Earnings Call Transcript
Key Points
- Pro Medicus Ltd (PMCUF) reported a 28.4% increase in revenue and a circa 30% rise in underlying EBIT, indicating strong financial performance.
- The company secured seven new contracts totaling $280 million, a significant increase compared to previous years.
- Pro Medicus Ltd (PMCUF) completed six cloud-based implementations, showcasing its capability in cloud technology.
- The company has a highly scalable software-only model with no CapEx, contributing to its strong EBIT margins.
- Pro Medicus Ltd (PMCUF) has a robust pipeline with opportunities across all market segments, indicating potential for future growth.
- The company faces competition from other vendors, with some contracts lost due to pricing issues.
- There is a risk of potential price pressure in the future due to advancements in AI and competition.
- The implementation of large contracts like Trinity is complex and time-consuming, which could impact revenue timing.
- The share price has experienced volatility, which may reflect market concerns or misunderstandings about the company's AI strategy.
- Pro Medicus Ltd (PMCUF) has a significant unrealized gain from its investment in 4DMedical, which is subject to market volatility and cannot be realized before the two-year term.
Thanks very much. Good morning, everybody, and thanks for joining us. As most of you would know, we are a company in three jurisdictions. Melbourne, our corporate headquarters; Berlin, where we do all the R&D and support center for Visage product; and the US, which is our main market where approximately 90% of our revenue is derived from.
We have two product sets. Here in Australia, we developed a Visage RIS, which does all the scheduling billing back-office interface to payers for some of the radiology groups in Australia. The Visage 7 product, on the other hand, is a clinical product. It's the radiologist desktop and it's the one that we are selling in the US.
In terms of the results, we felt all of our figures headed in the right direction. Revenue was up 28.4%. Our underlying EBIT was up circa 30%. Our EBIT margins period on period increased. Our cash investment -- cash and investments went up by 5.3% despite a buyback increased dividends and an investment of $10 million that we made
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
